External broker reports(aggregated public sources), CMB International

CMB International

External broker reports(aggregated public sources)

Incorporated in Hong Kong, supported by the mainland and targeting in global market, CMB International Capital Corporation Limited (“CMBI”) is an integrated financial institution providing comprehensive and professional services. As a wholly-owned subsidiary of China Merchants Bank ("CMB"), by leveraging on the Group’s synergy and coordination in domestic and overseas markets, as well as CMB’s strong resources and outstanding social reputation, CMBI and its subsidiaries have been actively implementing diversified business strategies and set up an overall layout of main business segments including Corporate Finance, Asset Management, Wealth Management, Global Markets and Structured Finance, etc. Adhering to the philosophy of “being clients oriented and increasing our own values by the way of creating value for clients”, CMBI endeavors to provide quality and integrated financial services to institutional, corporate and individual customers both domestic and overseas including Hong Kong IPO sponsorship and underwriting, share placement and rights issue for listed companies, financial advisors, bonds issuance services, asset management, direct investment, wealth management, equity sales and trading, etc.

Equity Bottom-Up

<ul><li>Strong sales growth continued in 4Q22, mainly driven by zanubrutinib.</li><li>In 4Q22, BeiGene recorded US$339mn product sales (-3% QoQ, +72% YoY).</li><li>Zanubrutinib (BTK) maintained a strong sales momentum, with sales increasing +13% QoQ or +101% YoY to US$176mn in 4Q22, driven by the overseas sales (especially in the US). </li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong sales growth continued in 4Q22, mainly driven by zanubrutinib.In 4Q22, BeiGene recorded US$339mn product sales (-3% QoQ, +72% YoY).Zanubrutinib (BTK) maintained a strong sales momentum, with sales increasing +13% QoQ or +101% YoY to US$176mn in 4Q22, driven by the overseas sales (especially in the US). Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL

<ul><li>Strong sales growth continued. BeiGene continued strong sales momentum in 3Q22, similar to 2Q22, with the product revenue in 3Q22 reaching US$349.5mn (+15% QoQ in 3Q22 vs +16% QoQ in 2Q22).</li><li>Sales of zanubrutinib (BTK) in 3Q22 increased to US$155.5mn with a QoQ growth rate of 21% (vs +23% QoQ in 2Q22), mainly driven by the strong sales in the overseas markets.</li><li>Tislelizumab (PD-1) also maintained strong growth in 3Q22, with sales increased by 22% QoQ, reaching US$128.2mn (vs +20% QoQ growth rate in 2Q22).</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Strong sales growth continued. BeiGene continued strong sales momentum in 3Q22, similar to 2Q22, with the product revenue in 3Q22 reaching US$349.5mn (+15% QoQ in 3Q22 vs +16% QoQ in 2Q22).Sales of zanubrutinib (BTK) in 3Q22 increased to US$155.5mn with a QoQ growth rate of 21% (vs +23% QoQ in 2Q22), mainly driven by the strong sales in the overseas markets.Tislelizumab (PD-1) also maintained strong growth in 3Q22, with sales increased by 22% QoQ, reaching US$128.2mn (vs +20% QoQ growth rate in 2Q22).Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Strong Sales Momentum Maintained in 3Q22

<ul><li>Superiority in PFS of zanubrutinib vs ibrutinib in r/r CLL. BeiGene announced superiority in PFS of BRUKINSA (zanubrutinib) vs ibrutinib in the final PFS analysis of the global Ph3 ALPINE trial in patients with r/r CLL, as assessed by both an independent review committee (IRC) and investigator.</li><li>In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and Australia (9%).</li><li>The detailed data will be disclosed at an upcoming medical conference. Zanubrutinib has previously demonstrated PFS benefit at the interim analysis of ALPINE trial.</li></ul>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Superiority in PFS of zanubrutinib vs ibrutinib in r/r CLL. BeiGene announced superiority in PFS of BRUKINSA (zanubrutinib) vs ibrutinib in the final PFS analysis of the global Ph3 ALPINE trial in patients with r/r CLL, as assessed by both an independent review committee (IRC) and investigator.In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and Australia (9%).The detailed data will be disclosed at an upcoming medical conference. Zanubrutinib has previously demonstrated PFS benefit at the interim analysis of ALPINE trial.Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

BeiGene (BGNE US) – Superior PFS Vs Ibrutinib

China

BeiGene, Ltd. operates as a commercial stage biopharmaceutical company. The Company focuses on discovery, development, and commercialization of molecularly targeted and immuno-oncology drugs for the treatment of cancer. BeiGene serves patients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

BeiGene (6160 HK)

BeiGene (BGNE US) – Expect strong sales in 2023 driven by the US approval of zanubrutinib in CLL

Strong sales growth continued in 4Q22, mainly driven by zanubrutinib. In 4Q22, BeiGene recorded US$339mn product sales (-3% QoQ, +72% YoY).

CMB International

BeiGene (BGNE US) – Strong Sales Momentum Maintained in 3Q22

BeiGene continued strong sales momentum in 3Q22, similar to 2Q22, with the product revenue in 3Q22 reaching US$349.5mn (+15% QoQ in 3Q22 vs +16%...

CMB International

BeiGene (BGNE US) – Superior PFS Vs Ibrutinib

In this head-to-head trial, a total of 652 r/r CLL/SLL patients were enrolled across Europe (60%), the US (17%), China (14%), New Zealand and...

CMB International

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)